<DOC>
	<DOCNO>NCT01666119</DOCNO>
	<brief_summary>This open label study opioid dependent subject maintain stabilize dose Suboxone tablet film . The purpose ass safety tolerability BEMA Buprenorphine NX administer daily 12 week opioid dependent subject stabilize Suboxone ( buprenorphine/naloxone ) tablets film . Eligible subject convert approximately equal dose BEMA Buprenorphine NX . This dose take throughout 12-week treatment period dose adjustment clinically indicate either control opioid dependence adverse event ( AEs ) .</brief_summary>
	<brief_title>An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects</brief_title>
	<detailed_description>This open label study opioid dependent subject maintain stabilize dose Suboxone tablet film . Eligible subject convert approximately equal dose BEMA Buprenorphine NX . This dose take throughout 12-week treatment period dose adjustment clinically indicate either control opioid dependence adverse event ( AEs ) . Subjects monitor evidence buccal irritation attribute application BEMA Buprenorphine NX film opioid dependence control accord Clinical Guidelines Use Buprenorphine Treatment Opioid Addiction - A Treatment Improvement Protocol ( TIP 40 ) guideline use buprenorphine management opioid dependence . The total duration participation subject approximately 18 week include Screening period ( subject continue take Suboxone tablet film ) , Baseline visit , 12-week open label treatment period ( subject take BEMA Buprenorphine NX film Day 84 visit , subject return prior Suboxone treatment ) , Follow-up Visit . Vital sign , pulse oximetry , opioid withdrawal symptom , adverse event ( AEs ) , oral examination , concomitant medication assess interval throughout study . Clinical laboratory assessment , urine toxicology buprenorphine testing , 12-lead electrocardiogram ( ECGs ) also perform .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>1 . Written inform consent obtain Screening , prior study procedure perform 2 . Male nonpregnant nonnursing female . A female childbearing potential eligible participate study pregnant , use acceptable method birth control 3 . Subject age 18 65 year age , inclusive 4 . Diagnosis opioid dependence per Diagnostic Statistical Manual Mental Disorders 4th edition ( text revision ) ( DSMIVTR ) criteria past 12 month include physical dependence opioids addiction compulsive use despite harm 5 . Currently take stable , single daily dose 16/4 32/8 mg Suboxone tablets film ( buprenorphine/naloxone ) least 30 day 6 . Subject good general health ; clinically significant finding medical history , physical examination , safety laboratory test ECG judgment investigator screen . Serum creatinine , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) value must within 3times upper limit normal ( ULN ) . Pulse oximetry must ≥96 % , systolic blood pressure ≥110 mmHg , diastolic blood pressure ≥65 mmHg . 1 . Hypokalemia , hypomagnesemia , clinically unstable cardiac disease , include : unstable atrial fibrillation , symptomatic bradycardia , unstable congestive heart failure , active myocardial ischemia , clinically significant arrhythmias 2 . History Long QT Syndrome , immediate family member condition 3 . Currently take Class IA antiarrhythmic medication ( eg , quinidine , procainamide , disopyramide ) Class III antiarrhythmic medication ( eg , sotalol , amiodarone , dofetilide ) 4 . Uncontrolled hypertension define systolic blood pressure &gt; 170 mmHg diastolic blood pressure &gt; 90 mmHg Baseline 5 . Pulse oximetry ≤93 % Baseline , regardless cause 6 . Clinically significant abnormality 12lead ECG , include QTc interval &gt; 490 millisecond 7 . Use medication , nutraceutical herbal product CYP3A4 inhibition induction property within past 30 day ( see Appendix 4 list applicable drug ) . This exclusion also extend grapefruit juice grapefruit juicecontaining product well St. John 's wort St. John 's wortcontaining product ( prescription nonprescription drug , vitamin , mineral , dietary/herbal supplement ) . 8 . Diagnosis moderate severe hepatic impairment 9 . Use investigational drug device within last 30 day 10 . Participation previous clinical study BEMA Buprenorphine NX BEMA Buprenorphine 11 . History hypersensitivity , allergy , intolerance buprenorphine , naloxone , related drug 12 . Pierced tongue mouth 13 . Any clinically significant abnormality buccal mucosa could impact drug absorption 14 . Suicidal risk , determine meeting follow : 1 . History suicidal ideation ≤ 3 month prior Baseline score 4 ( intent act ) 5 ( specific plan intent ) eCSSRS 2 . History suicidal behavior ≤ 1 year prior Baseline ( actual attempt , interrupt attempt , abort attempt and/or preparatory acts/behavior ) eCSSRS 15 . A history current evidence clinically significant disorder condition opinion investigator , would jeopardize safety subject impact validity study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Opioid dependence</keyword>
	<keyword>Suboxone</keyword>
	<keyword>addiction</keyword>
	<keyword>BEMA Buprenorphine NX</keyword>
	<keyword>oral transmucosal</keyword>
</DOC>